Videos

Vincent Picozzi, MD, discusses treatment for patients with pancreatic cancer who undergo surgery. Overall, the landscape lacks data on how to optimally sequence chemotherapy in patients with resectable disease.

David Miklos, MD, discusses exciting data for the use of chimeric antigen receptor T-cell therapy as treatment of patients with diffuse large B-cell lymphoma.

A 59-Year Old Woman With Stage IIIC Ovarian Cancer

Georgina V. Long, BSc, PhD, MBBS, FRACP, discusses the design and efficacy of the phase III CheckMate 067 trial for patients with advanced melanoma.<br /> &nbsp;

Scott Kopetz, MD, PhD, discusses&nbsp;the combination of regorafenib and nivolumab for patients with colorectal cancerthe combination of regorafenib and nivolumab for patients with colorectal cancer.

A 69-Year Old Man With Metastatic BRAF V600E-Mutated Metastatic NSCLC

Prasad S. Adusumilli, MD, FACS, discusses where he sees chimeric antigen receptor T-cell therapy fitting into the treatment landscape for patients with solid tumors.

Luis E. Raez, MD, discusses targeted therapies for patients with lung cancer who have genetic alterations.

Jennifer Woyach, MD, discusses the frontline options for the treatment of patients with chronic lymphocytic leukemia.

Tania Jain, MBBS, discusses the current treatment options for graft-versus-host-disease, a known complication of allogeneic stem cell transplant, which is the only curative treatment option for patients with myelofibrosis.

Rajneesh Nath, MD, discusses the rationale for phase III SIERRA trial, which evaluated the anti-CD45 monoclonal antibody apamistamab followed by fludarabine/total body irradiation and allogeneic hematopoietic cell transplantation in patients with relapsed/refractory acute myeloid leukemia.

Stephen J. Freedland, MD, discusses real-world data for enzalutamide as treatment of patients with metastatic castration-resistant prostate cancer compared with data from the phase III PREVAIL study.

Heather Wakelee, MD, discusses how physicians are treating patients with advanced lung cancer using targeted therapies, such as EGFR tyrosine kinase inhibitors in patients harboring an&nbsp;EGFR&nbsp;mutation.

Ruben Mesa, MD, discusses the current challenges in the treatment landscape for researchers treating myelofibrosis (MF) and how a greater understanding of why patients relapse will help investigators overcome these challenges.

Sonali M. Smith, MD, discusses&nbsp;how to handle patients with follicular lymphoma when they relapse, especially if they are early progressors.<br /> &nbsp;

Nathan A. Pennell, MD, PhD, discusses the role of molecular testing when treating and managing patients with&nbsp;<a>lung cancer.</a>&nbsp;He shares his advice on what to do for patients who need therapy immediately, as well.

Jeff P. Sharman, MD, discusses the secondary end points from the&nbsp;<u><strong><a href="https://www.targetedonc.com/conference/ash-2019/patients-with-cll-treated-on-the-elevatetn-trial-experience-improved-pfs-with-acalabrutinib">phase III ELEVATE-TN&nbsp;trial</a></strong></u>, which evaluated the role of acalabrutinib, either as a single agent or in combination with obinutuzumab in patients with treatment-naive chronic lymphocytic leukemia.